Travere Therapeutics (Travere Therapeutics) Operating Cash Flow per Share : $-3.80 (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Operating Cash Flow per Share?

Travere Therapeutics's operating cash flow per share for the three months ended in Dec. 2023 was $-0.92. Travere Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.80.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -61.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -33.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Travere Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

TVTX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -488 Med: -61.3 Max: 58.3
Current: -61.3

During the past 13 years, Travere Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 58.30% per year. The lowest was -488.00% per year. And the median was -61.30% per year.

TVTX's 3-Year OCF Growth Rate is ranked worse than
91.34% of 1235 companies
in the Biotechnology industry
Industry Median: 3.5 vs TVTX: -61.30

Travere Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Travere Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Operating Cash Flow per Share Chart

Travere Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-1.38

-0.90

-0.25

-2.92

-3.77

Travere Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.85	-1.19	-0.91	-0.78	-0.92

Competitive Comparison of Travere Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Travere Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Travere Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Price-to-Operating-Cash-Flow falls into.

Travere Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Travere Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-280.021	/	74.267
	=	-3.77

Travere Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-70.473	/	76.499
	=	-0.92

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.80

Travere Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Travere Therapeutics (Travere Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130

Website

https://www.travere.com

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Executives

Jula Inrig	officer: Chief Medical Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Peter Heerma	officer: Chief Commercial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote	officer: Senior Vice President, R&D	C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline	officer: Chief Financial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube	director, officer: Chief Executive Officer	3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Elizabeth E Reed	officer: SVP, GC & Corporate Secretary	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Sandra Calvin	officer: VP, Corp Controller and CAO	3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Laura Clague	officer: Chief Financial Officer	370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams	director	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg	officer: Chief Medical Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane	officer: Chief Operating Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Sandra Poole	director	830 WINTER STREET, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066